Nutritional Assessment in Children With Cardiomyopathy

September 29, 2026 updated by: Manar Abd El-Aziz Anwar Abd EL-Aziz, Assiut University

Nutritional Assessment in Children With Cardiomyopathy: Prevalence and Pattern of Malnutrition

This cross-sectional study aims to determine the prevalence and pattern of malnutrition (acute wasting, chronic stunting, and micronutrient deficiency) among children with cardiomyopathy attending the Pediatric Cardiology Unit at Assiut University Children's Hospital.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Cardiomyopathy in children encompasses a heterogeneous group of primary myocardial disorders (dilated, hypertrophic, and restrictive) that represent a leading cause of chronic heart failure and a common indication for heart transplantation in the pediatric age group.

Malnutrition is now recognized as a common and clinically significant comorbidity in pediatric cardiomyopathy. Data from the Pediatric Cardiomyopathy Registry indicate that nearly a quarter of children with dilated cardiomyopathy are malnourished at presentation, while pooled estimates from adult heart failure populations report a malnutrition prevalence approaching half of all patients, with malnutrition independently associated with increased mortality.

This cross-sectional study will include children aged 1 month to 18 years with an established diagnosis of cardiomyopathy confirmed by echocardiography. Nutritional status will be assessed using anthropometric measurements (weight, height, MUAC, BMI-for-age z-scores), the STRONGkids screening tool, biochemical markers, and dietary assessment. The prevalence and pattern of malnutrition will be determined.

Study Type

Observational

Enrollment (Estimated)

108

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Children aged 1 month to 18 years with an established diagnosis of cardiomyopathy (dilated, hypertrophic, or restrictive) confirmed by echocardiography, attending or admitted to the Pediatric Cardiology Unit at Assiut University Children's Hospital.

Description

Inclusion Criteria:

  • Children aged 1 month to 18 years.
  • Established diagnosis of cardiomyopathy (dilated, hypertrophic, or restrictive) confirmed by echocardiography.
  • Attending or admitted to the Pediatric Cardiology Unit at Assiut University Children's Hospital.
  • Written informed consent from parent/legal guardian.

Exclusion Criteria:

  • Known chronic conditions with an independent, primary effect on nutritional status (e.g., celiac disease, chronic kidney disease, malignancy).
  • Genetic/metabolic syndromes with intrinsic growth failure unrelated to cardiac status.
  • Refusal of parental/guardian informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
Children With Cardiomyopathy

Children aged 1 month to 18 years with an established diagnosis of cardiomyopathy (dilated, hypertrophic, or restrictive) confirmed by echocardiography, attending or admitted to the Pediatric Cardiology Unit at Assiut University Children's Hospital.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Title: Prevalence of malnutrition
Time Frame: Baseline

Proportion of children with cardiomyopathy who have malnutrition based on anthropometric z-scores according to WHO growth standards.

Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of children at nutritional risk by STRONGkids
Time Frame: Baseline

Proportion of children classified as at nutritional risk according to the STRONGkids screening tool.

Baseline
Mean left ventricular ejection fraction
Time Frame: Baseline

Mean left ventricular ejection fraction (LVEF) measured by echocardiography in percentage.

Baseline
Mean serum albumin
Time Frame: Baseline

Mean serum albumin level in g/dL.

Baseline
Mean body mass index for age z-score
Time Frame: Baseline

Mean BMI-for-age z-score according to WHO growth standards.

Baseline
Proportion of children with feeding difficulties
Time Frame: Baseline

Proportion of children with reported feeding difficulties assessed by structured dietary assessment.

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Gamal A Asker, prof, Pediatrics Department, Assiut University Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 30, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

February 25, 2028

Study Registration Dates

First Submitted

September 29, 2026

First Submitted That Met QC Criteria

September 29, 2026

First Posted (Actual)

October 5, 2026

Study Record Updates

Last Update Posted (Actual)

October 5, 2026

Last Update Submitted That Met QC Criteria

September 29, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Nutrition-CMP-Assiut-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.